HealthQuill Acquisition
McKesson Corporation, the ninth-largest company by revenue in the US, will acquire Community Oncology Revitalization Enterprise Ventures, for $2.4 billion in cash to expand its oncology portfolio.
Drugs Health Pharma

McKesson Corp., to acquire Core Ventures for $2.4 billion in cash

McKesson Corporation, the ninth-largest company by revenue in the US, will acquire Community Oncology Revitalization Enterprise Ventures, for $2.4 billion in cash to expand its.

Read More
Johnson & Johnson plans to acquire Israel’s privately-held V-Wave Ltd., for an upfront payment of $600 million, according to a statement from the US-based company.
Drugs Health Pharma

J&J plans to acquire Israel’s V-Wave by paying $600 million upfront

Johnson & Johnson plans to acquire Israel’s privately-held V-Wave Ltd., for an upfront payment of $600 million, according to a statement from the.

Read More
India’s Mankind Pharma will buy Mumbai-based Bharat Serums and Vaccines for 136 billion rupees ($1.63 billion), according to a company statement.
Drugs Health Pharma

Mankind Pharma buys Bharat Serum and Vaccines for $1.6 billion

India’s Mankind Pharma will buy Mumbai-based Bharat Serums and Vaccines for 136 billion rupees ($1.63 billion), according to a company statement.

Read More
Agilent Technologies Inc., will acquire Canada-based Biovectra, a contract development and manufacturing company, for $925 million, according to a company statement.
Drugs Health Pharma

US-based Agilent Technologies to acquire Canada’s Biovectra for $925m

HQ Team July 23, 2024: Agilent Technologies Inc., will acquire Canada-based Biovectra, a contract development and manufacturing company, for $925 million, according to.

Read More
AstraZeneca announced the completion of the acquisition of Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, for $2.4 billion.
Drugs Health Pharma

AstraZeneca completes $2.4 billion acquisition of Fusion Pharma

AstraZeneca announced the completion of the acquisition of Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, for $2.4 billion.

Read More
Johnson & Johnson has agreed to buy the rights for an investigational skin disorder treatment from Numab Therapeutics for $1.25 billion.
Drugs Health Pharma

J & J to buy rights for experimental skin disorder drug for $1.25 billion

Johnson & Johnson has agreed to buy the rights for an investigational skin disorder treatment from Numab Therapeutics for $1.25 billion.

Read More
Johnson & Johnson will acquire Proteologix, Inc., a privately-held biotechnology company, for $850 million in cash, according to a statement.
Drugs Health Pharma

Johnson & Johnson to buy Proteologix Inc., for $850 million in cash

HQ Team May 17, 2024: Johnson & Johnson will acquire Proteologix, Inc., a privately-held biotechnology company, for $850 million in cash, according to.

Read More
Britain’s Competition and Markets Authority (CMA) expressed concerns over Theramex's planned acquisition of Femoston and Duphaston stating it may reduce competition and choice for hormone replacement therapy (HRT) treatments in the country.
Drugs Health Pharma

Britain’s CMA raises concern over Theramex’s Femoston buy

HQ Team April 4, 2024: Britain’s Competition and Markets Authority (CMA) expressed concerns over Theramex’s planned acquisition of Femoston and Duphaston stating it.

Read More
Novo Nordisk, one of the world’s most valuable companies, will acquire Germany-based Cardior Pharmaceuticals, a firm that specialises in heart diseases, for up to 1.03 billion euros ($1.1 billion).
Drugs Health Pharma

Novo to buy Cardior for $1.1b to expand cardiovascular segment

HQ Team March 25, 2024: Novo Nordisk, one of the world’s most valuable companies, will acquire Germany-based Cardior Pharmaceuticals, a firm that specialises.

Read More
Anglo-Swedish drugmaker, AstraZeneca will acquire clinical-stage Fusion Pharmaceuticals for $2 billion in cash to get access to the latter’s radioconjugates to treat cancer.
Drugs Health Pharma

AstraZeneca to acquire Fusion Pharmaceuticals for $2 billion in cash

HQ Team March 20, 2024: Anglo-Swedish drugmaker, AstraZeneca will acquire clinical-stage Fusion Pharmaceuticals for $2 billion in cash to get access to the.

Read More
X